The annual AIM-HI Women’s Venture Competition provides critical early-stage funding for women entrepreneurs in oncology. The winning company receives up to a $1 million equity investment from AIM-HI and co-investors, subject to due diligence and negotiations, to fund pre-clinical investigations. Ultimately, this financing helps to bring next-generation therapeutics, diagnostics, and prevention technologies to patients.
In light of the extenuating weather conditions and power outages in multiple states, the Deadline to Apply for the 2023 AIM-HI Women’s Venture Competition has been extended to Sunday, March 19, at 11:55 PM EST.
In addition to seed-stage financing, AIM-HI provides other essential resources to participating startups, including:
A startup’s success depends on its leadership. We match highly coachable female scientist-entrepreneurs with experienced industry leaders to improve their chance of success.
We focus on developing time-efficient, strategic connections by helping women scientist-entrepreneurs build out their teams.
AIM-HI is part of a global network of innovators, investors, and influencers in the oncology subsector of the life sciences industry. We utilize this network for investment and market expansion purposes for our selected woman scientist-entrepreneurs.
Together, we can make the next generation of cancer treatments a reality.